Breast cancer is the most common cancer and the deadliest among women worldwide.
Estrogen signaling is closely associated with hormone-dependent breast cancer (estrogen …

Breast cancer is the most common cancer worldwide. The occurrence of breast cancer is
associated with many risk factors, including genetic and hereditary predisposition. Breast …

The histone deacetylase (HDAC) enzymes, a class of epigenetic regulators, are historically
well established as attractive therapeutic targets. During investigation of trends within …

It is now 30 years since the first report of a potent zinc-dependent histone deacetylase
(HDAC) inhibitor appeared. Since then, five HDAC inhibitors have received regulatory …

Cancer development is driven by the accumulation of alterations affecting the structure and
function of the genome. Whereas genetic changes disrupt the DNA sequence, epigenetic …

The role of genetic and epigenetic factors in tumor initiation and progression is well
documented. Histone deacetylases (HDACs), histone methyl transferases (HMTs), and DNA …

Numerous agents targeting various phosphatidylinositol 3-kinase (PI3K) pathway
components, including PI3K, AKT and mTOR, have been tested in oncology clinical trials …

Genetic mutations and abnormal gene regulation are key mechanisms underlying
tumorigenesis. Nucleosomes, which consist of DNA wrapped around histone cores …

Histone deacetylase (HDAC) serves as a critical molecular regulator in the pathobiology of
various malignancies and have garnered attention as a viable target for therapeutic …

Dysregulation of histone deacetylases (HDACs) is closely related to tumor development and
progression. As promising anticancer targets, HDACs have gained a great deal of research …